Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Global Clinical Trial to Evaluate the Efficacy and Safety of a Combination of APL-1202 with Bacillus Calmette Guerin (BCG) in Non-Muscle Invasive Bladder Cancer (NMIBC) Patients

Next Previous
Search
Trial Profile

A Phase II Global Clinical Trial to Evaluate the Efficacy and Safety of a Combination of APL-1202 with Bacillus Calmette Guerin (BCG) in Non-Muscle Invasive Bladder Cancer (NMIBC) Patients

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 19 Apr 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BCG (Primary) ; Nitroxoline (Primary)
  • Indications Bladder cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Asieris Pharmaceuticals

    • Most Recent Events

    • 17 Apr 2024 According to Asieris Pharmaceuticals media release, company intends to promptly communicate with the National Medical Products Administration's Center for Drug Evaluation (CDE) and submit an application for clinical trial.
    • 25 Jun 2019 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top